Literature DB >> 31473221

The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era.

Vanessa Chilunda1, Tina M Calderon1, Pablo Martinez-Aguado1, Joan W Berman2.   

Abstract

Approximately 37 million people worldwide are infected with human immunodeficiency virus (HIV). One highly significant complication of HIV infection is the development of HIV-associated neurocognitive disorders (HAND) in 15-55% of people living with HIV (PLWH), that persists even in the antiretroviral therapy (ART) era. The entry of HIV into the central nervous system (CNS) occurs within 4-8 days after peripheral infection. This establishes viral reservoirs that may persist even in the presence of ART. Once in the CNS, HIV infects resident macrophages, microglia, and at low levels, astrocytes. In response to chronic infection and cell activation within the CNS, viral proteins, inflammatory mediators, and host and viral neurotoxic factors produced over extended periods of time result in neuronal injury and loss, cognitive deficits and HAND. Substance abuse is a common comorbidity in PLWH and has been shown to increase neuroinflammation and cognitive disorders. Additionally, it has been associated with poor ART adherence, and increased viral load in the cerebrospinal fluid (CSF), that may also contribute to increased neuroinflammation and neuronal injury. Studies have examined mechanisms that contribute to neuroinflammation and neuronal damage in PLWH, and how substances of abuse exacerbate these effects. This review will focus on how substances of abuse, with an emphasis on methamphetamine (meth), cocaine, and opioids, impact blood brain barrier (BBB) integrity and transmigration of HIV-infected and uninfected monocytes across the BBB, as well as their effects on monocytes/macrophages, microglia, and astrocytes within the CNS. We will also address how these substances of abuse may contribute to HIV-mediated neuropathogenesis in the context of suppressive ART. Additionally, we will review the effects of extracellular dopamine, a neurotransmitter that is increased in the CNS by substances of abuse, on HIV neuropathogenesis and how this may contribute to neuroinflammation, neuronal insult, and HAND in PLWH with active substance use. Lastly, we will discuss some potential therapies to limit CNS inflammation and damage in HIV-infected substance abusers.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; CNS; HIV associated neurocognitive disorders; Macrophages; Monocytes; Substances of abuse

Year:  2019        PMID: 31473221      PMCID: PMC6889827          DOI: 10.1016/j.brainres.2019.146426

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  310 in total

1.  Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein.

Authors:  Sonia Mediouni; Albert Darque; Gilbert Baillat; Isabelle Ravaux; Catherine Dhiver; Herve Tissot-Dupont; Malika Mokhtari; Herve Moreau; Catherine Tamalet; Corinne Brunet; Pascale Paul; Francoise Dignat-George; Andreas Stein; Philippe Brouqui; Stephen A Spector; Grant R Campbell; Erwann P Loret
Journal:  Infect Disord Drug Targets       Date:  2012-02

2.  Role of Sigma Receptor in Cocaine-Mediated Induction of Glial Fibrillary Acidic Protein: Implications for HAND.

Authors:  Lu Yang; Honghong Yao; Xufeng Chen; Yu Cai; Shannon Callen; Shilpa Buch
Journal:  Mol Neurobiol       Date:  2015-01-29       Impact factor: 5.590

3.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

4.  The TNF-α/NF-κB signaling pathway has a key role in methamphetamine-induced blood-brain barrier dysfunction.

Authors:  Vanessa Coelho-Santos; Ricardo A Leitão; Filipa L Cardoso; Inês Palmela; Manuel Rito; Marcos Barbosa; Maria A Brito; Carlos A Fontes-Ribeiro; Ana P Silva
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-22       Impact factor: 6.200

5.  CCR2 on Peripheral Blood CD14+CD16+ Monocytes Correlates with Neuronal Damage, HIV-Associated Neurocognitive Disorders, and Peripheral HIV DNA: reseeding of CNS reservoirs?

Authors:  Mike Veenstra; Desiree A Byrd; Matilde Inglese; Korhan Buyukturkoglu; Dionna W Williams; Lazar Fleysher; Ming Li; Lucio Gama; Rosiris León-Rivera; Tina M Calderon; Janice E Clements; Susan Morgello; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2018-07-06       Impact factor: 4.147

6.  HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations.

Authors:  Michelle M Jacobs; Jacinta Murray; Desiree A Byrd; Yasmin L Hurd; Susan Morgello
Journal:  J Neurovirol       Date:  2013-10       Impact factor: 2.643

Review 7.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

8.  Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.

Authors:  Wenfei Wang; Mark S Sonders; Okechukwu T Ukairo; Helen Scott; Megan K Kloetzel; Christopher K Surratt
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

9.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

10.  Macrophages but not Astrocytes Harbor HIV DNA in the Brains of HIV-1-Infected Aviremic Individuals on Suppressive Antiretroviral Therapy.

Authors:  Allen Ko; Guobin Kang; Julian B Hattler; Hadiza I Galadima; Junfeng Zhang; Qingsheng Li; Woong-Ki Kim
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-07       Impact factor: 4.147

View more
  13 in total

1.  Progressive Degeneration and Adaptive Excitability in Dopamine D1 and D2 Receptor-Expressing Striatal Neurons Exposed to HIV-1 Tat and Morphine.

Authors:  Arianna R S Lark; Lindsay K Silva; Sara R Nass; Michael G Marone; Michael Ohene-Nyako; Therese M Ihrig; William D Marks; Viktor Yarotskyy; A Rory McQuiston; Pamela E Knapp; Kurt F Hauser
Journal:  Cell Mol Neurobiol       Date:  2022-06-13       Impact factor: 5.046

Review 2.  Advances in the Experimental Models of HIV-Associated Neurological Disorders.

Authors:  Susmita Sil; Palsamy Periyasamy; Annadurai Thangaraj; Fang Niu; Divya T Chemparathy; Shilpa Buch
Journal:  Curr HIV/AIDS Rep       Date:  2021-08-24       Impact factor: 5.495

3.  Methamphetamine Dysregulates Macrophage Functions and Autophagy to Mediate HIV Neuropathogenesis.

Authors:  John M Barbaro; Simone Sidoli; Ana Maria Cuervo; Joan W Berman
Journal:  Biomedicines       Date:  2022-05-27

Review 4.  A "Drug-Dependent" Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV.

Authors:  María Amparo Assis; Pedro Gabriel Carranza; Emilio Ambrosio
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

Review 5.  Mechanisms of neuronal dysfunction in HIV-associated neurocognitive disorders.

Authors:  Elena Irollo; Jared Luchetta; Chunta Ho; Bradley Nash; Olimpia Meucci
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

Review 6.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

Review 7.  An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems.

Authors:  Nuti Desai; Leah Burns; Yuqing Gong; Kaining Zhi; Asit Kumar; Nathan Summers; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-08-31       Impact factor: 4.481

8.  Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV.

Authors:  Stephanie M Matt; Emily A Nickoloff-Bybel; Yi Rong; Kaitlyn Runner; Hannah Johnson; Margaret H O'Connor; Elias K Haddad; Peter J Gaskill
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

9.  Using mobile health technologies to test the association of cocaine use with sexual desire and risky sexual behaviors among people with and without HIV who use illicit stimulants.

Authors:  Yunan Xu; Sheri L Towe; Shakiera T Causey; Christina S Meade
Journal:  Drug Alcohol Depend       Date:  2021-05-20       Impact factor: 4.852

10.  Morphine exposure exacerbates HIV-1 Tat driven changes to neuroinflammatory factors in cultured astrocytes.

Authors:  Kenneth Chen; Thienlong Phan; Angel Lin; Luca Sardo; Anthony R Mele; Michael R Nonnemacher; Zachary Klase
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.